The company was established in 1980 in the United Arab Emirates (as a public joint-stock company). It is considered one of the largest pharmaceutical manufacturers in the Middle East and North Africa, distributing medicines to over 40 countries. The company owns factories in the UAE that specialize in the production of tablets, syrups, and suspensions. It has also established several factories in Ethiopia, Bangladesh, and Saudi Arabia as part of its ongoing international expansion strategy. The company offers a diverse range of products targeting key therapeutic areas, including wound care, anemia, women’s health, primary care for the elderly, pediatric primary care, gastrointestinal medications, pain management, cardiovascular and respiratory care, and consumer health. The company signed a memorandum of understanding with the Ministry of Industry and Advanced Technology to build the first factory in the Middle East for the production of a long-acting biological insulin substitute. Furthermore, Planet Pharmacies has continued to enhance its distribution and retail sales capabilities in the pharmaceutical healthcare sector in the UAE, Saudi Arabia, and Oman. In 2022, the company’s revenues in its main markets continued to grow, reflecting its position in the region, thanks to the success of its flagship brand. Gulf Pharmaceutical Industries (Julphar) launched new products as part of its strategy and continued to implement its action plan effectively. The company’s capital is approximately 1.155 billion AED (about 96 million Kuwaiti dinars), with ACDIMA holding a 9.15% stake in the company’s capital. The company’s sales in 2022 amounted to around 134 million Kuwaiti dinars compared to approximately 95 million Kuwaiti dinars in 2021, and the company recorded a net loss of about 2.9 million Kuwaiti dinars in 2022 compared to a profit of approximately 4.2 million Kuwaiti dinars in 2021